A5041338814- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
- BRCA gene mutations in cancer
- Advanced Breast Cancer Therapies
- Global Cancer Incidence and Screening
- Cardiac, Anesthesia and Surgical Outcomes
- HER2/EGFR in Cancer Research
- Medical Imaging Techniques and Applications
- Global Health and Surgery
- Radiomics and Machine Learning in Medical Imaging
- Lung Cancer Treatments and Mutations
- COVID-19 and healthcare impacts
- Colorectal Cancer Screening and Detection
- Multiple and Secondary Primary Cancers
- Cancer Immunotherapy and Biomarkers
- Advances in Oncology and Radiotherapy
- Genetic factors in colorectal cancer
- Cancer-related Molecular Pathways
The Netherlands Cancer Institute
2020-2023
European Organisation for Research and Treatment of Cancer
2020-2023
OLVG
2020
European Organisation for Research and Treatment of Cancer
2020
University Health Network
2018
Patients with 70-gene signature ultralow-risk breast cancers have shown excellent survival in historic cohorts, including randomized trials. The subgroup was characterized to help avoid overtreatment. We evaluated outcomes of patients the largest cohort date.Of 6,693 enrolled EORTC-10041/BIG-3-04 phase III MINDACT trial, profiling revealed an 1,000 (15%). Distant metastasis-free interval (DMFI) and cancer-specific (BCSS) were assessed stratified by result (high, low, ultralow) Kaplan-Meier...
506 Background: The 70-gene signature MammaPrint has been shown to identify breast cancer patients for whom adjuvant chemotherapy (CT) could be safely omitted even in the presence of unfavorable standard clinical-pathological criteria. MINDACT primary endpoint at 5 years median follow-up was met 2016 (Cardoso et al, NEJM 2016) with a distant metastasis free survival (DMFS) rate 94.7% (95% CI: 92.5-96.2) clinical high (C-High) / genomic low (G-Low) risk who received no CT. Longer is now...
PURPOSE A polygenic risk score (PRS) consisting of 313 common genetic variants (PRS ) is associated with breast cancer and contralateral cancer. This study aimed to evaluate the association PRS clinicopathologic characteristics of, survival following, METHODS Women invasive were included, 98,397 European ancestry 12,920 Asian ancestry, from Breast Cancer Association Consortium (BCAC), 683 women MINDACT trial. Associations between characteristics, including 70-gene signature for MINDACT,...
500 Background: Gene signatures have proven successful in identifying patients with a low risk of distant recurrence who could forego chemotherapy (CT) and are currently included international treatment guidelines for breast cancer. For the 70-gene signature (MammaPrint) an additional threshold was established within category to identify ultralow recurrence. In independent cohorts, these had excellent cancer specific survival at 15 years, suggesting that cancers represent indolent disease...
Background and context: Tumor, Node, Metastases (TNM) classification system provide valuable measures to researchers in facilitating the understanding of disparities outcomes allowing for comparison these over time. There is a lack multimodal formats disseminating comprehensive information education about cancer stage global community. To address this gap, Departments Radiation Oncology Cancer Education at Princess Margaret Centre (PM) (Toronto, Canada) collaboration with The Union...
Background: The MINDACT trial showed excellent 5-year distant metastasis-free survival (DMFS) of 94·7% (95%CI 92·5-96·2) in clinical high (C-High)/genomic low (G-Low) risk patients who did not receive chemotherapy. Long-term follow-up is presented.Methods: 6693 were enrolled 2007 to 2011. We reassessed DMFS rate at 5 years C-High/G-Low receiving chemotherapy (n=644) (primary analysis), updated and overall or (n=749 748, respectively) (secondary examined a potential age effect (< 50y vs >...
563 Background: A polygenic risk score (PRS) consisting of 313 single nucleotide polymorphisms (PRS ) is associated with breast cancer and contralateral cancer. One the most promising clinical applications for use PRS to provide a personalized assessment individualize screening programs. This study aimed evaluate association clinical-pathological characteristics survival Methods: Women European ancestry invasive were included, 98,397 women from Breast Cancer Association Consortium (BCAC) 683...
Abstract Background With 8.7 years follow-up, the prospective phase III randomized MINDACT trial (EORTC 10041/BIG3-04) continues to meet its primary objective, i.e. 95.1% (95%CI 93.1-96.6), 5-year distant metastasis-free survival (DMFS) in clinical high (C-High)/genomic low (G-Low) risk patients who did not receive adjuvant chemotherapy (ACT) (Cardoso et al., ASCO 2020). In addition, about half of had a (C-Low) defined by pre-specified clinical-pathological characteristics. Here, we...
Abstract Background With 8.7 years follow-up, the prospective phase III randomized MINDACT trial (EORTC 10041/BIG3-04) continues to meet its primary objective, i.e. 95.1% (95%CI 93.1-96.6), 5-year distant metastasis-free survival (DMFS) in clinical high (C-High)/genomic low (G-Low) risk patients who did not receive adjuvant chemotherapy (ACT) (Cardoso et al., ASCO 2020). In addition, about half of had a (C-Low) defined by pre-specified clinical-pathological characteristics. Here, we...